
South Africa Built a Medical Research Powerhouse. Trump Cuts Have Demolished It.
In Cape Town, South Africa, one of the world's foremost H.I.V. researchers has been spending a chunk of each day gently telling longtime workers and young doctoral students that the money is gone and so are their jobs. When the calls are done, she weeps in her empty office.
In the heart of Johannesburg, the lobby of a building that once housed hundreds of scientists is empty of people but choked with discarded office furniture and heaps of files hastily gathered from shuttered research sites.
South Africa has for decades been a medical research powerhouse, yet its stature has been little known to people outside the field. South Africa's scientists have been responsible for key breakthroughs against major global killers, including heart disease, H.I.V. and respiratory viruses such as Covid-19. They have worked closely with American researchers and have been awarded more research funding from the United States than any other country has received.
But a swift series of executive orders and budget cuts from the Trump administration have, in a matter of months, demolished this research ecosystem.
There are grim ramifications for human health worldwide, and also for pharmaceutical companies, including American giants such as Pfizer, Merck, Abbott and Gilead Sciences, which rely heavily on South Africa's research complex when they develop and test new drugs, vaccines and treatments.
'South Africa is the beacon,' said Dr. Harold Varmus, a professor of medicine at Cornell University who was awarded the Nobel Prize in medicine for his work on cancer biology and who was a director of the National Institutes of Health.
Want all of The Times? Subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Eli Lilly, Juvena Therapeutics Partner to Develop Muscle-Boosting Drugs Using AI Platform
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a partnership with Juvena Therapeutics to develop new muscle-boosting drugs. The collaboration is valued at over $650 million, with the majority of this sum tied to the achievement of specific development and commercialization milestones. The core of the partnership involves Eli Lilly using Juvena's AI-enabled screening platform, which is known as JuvNET. This platform specializes in mapping the therapeutic potential of proteins secreted by stem cells. By combining a vast database of secreted proteins with disease phenotypes, in silico and in vitro human cell screening, and other advanced capabilities, JuvNET is designed to identify promising drug candidates that can improve muscle health and body composition. Eli Lilly's interest in muscle-boosting drugs has surged in parallel with the popularity of GLP-1 weight-loss medication. These medications are effective for weight loss but can also lead to a reduction in lean muscle mass, which can impair physical function and increase the risk of falls and fractures, especially in older individuals and senior citizens. Eli Lilly aims to address this concern. Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals internationally. Juvena Therapeutics is a clinical-stage biotechnology company on a mission to research, develop, and commercialize tissue restorative biologics. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
35 minutes ago
- Yahoo
AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics
AbbVie Inc. (NYSE:ABBV) is one of the best stocks to buy for beginners now. In mid-May, AbbVie and ADARx Pharmaceuticals announced a collaboration and license option agreement. The partnership aims to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, such as neuroscience, immunology, and oncology. siRNA molecules are a class of genetic medicines capable of regulating gene expression and protein production by targeting messenger RNA (mRNA) to prevent the synthesis of disease-causing proteins. This differs from traditional approaches like antibodies and small molecules, which target existing proteins. The collaboration will combine ADARx's RNA discovery expertise and proprietary siRNA technology, which has the potential for sustained and precise mRNA silencing, with AbbVie's extensive experience in antibody engineering, antibody drug conjugates/ADCs, and tissue delivery approaches. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. Under the terms of the agreement, ADARx will receive an upfront payment of $335 million. Additionally, ADARx is eligible to receive several billion dollars in further contingent payments, which include option-related fees and milestone payments, as well as tiered royalties on any successfully commercialized products. AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches & develops, manufactures, commercializes, and sells medicines and therapies worldwide. ADARx Pharmaceuticals is a late clinical-stage biotech company that specializes in next-gen RNA therapeutics. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Cardinal Health (CAH) Affirms Long-Term Growth Raises Outlook
Cardinal Health, Inc. (NYSE:CAH) is . On June 12, the company raised its fiscal year 2025 diluted earnings per share guidance to between $8.15 and $8.20 from an initial guidance of between $8.05 and $8.15. The company also established a preliminary fiscal year 2026 guidance of between $9.10 and $9.30, affirming expected growth. A healthcare professional in a lab coat holding a microscope and looking at a slide under the lens. In addition, Cardinal Health is targeting a long-term compound annual growth rate of between 12% and 14% for its non-GAAP diluted EPS between 2026 and 2028. It also targets 5% to 7% long-term profit growth in its Pharmaceutical and Specialty Solutions segment. The company also targets $50 million of profit growth under its Global Medical Products and Distribution. Cardinal Health will achieve $10 billion in adjusted free cash flow over the next three years. It has already increased its baseline share repurchase plans to $750 million from $500 million. The company also plans to invest over $150 million in its Nuclear and Precision Health Solutions to support theranostics and PER product pipeline development. Cardinal Health, Inc. (NYSE:CAH) is a healthcare company that operates in various sectors, including pharmaceutical distribution, medical product manufacturing and distribution, and performance and data solutions for healthcare facilities. It provides solutions to different healthcare providers, from hospitals and clinics to pharmacies and home care services. While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data